TruScreen Group Limited Share Price

Current Share Price data for TruScreen Group Limited (NZX:TRU ASX:TRU)

ASX Listing
NZX Listing

TruScreen Group Financial Reports

FY22 Half Year Report
29.11.2021

2022 Half Year Report

Half Year Report for the period ended September 2021

FY21 Annual Report
30.6.2021

2021 Annual Report

Annual Report for the year ended March 2021

FY21 Half Year Report
4.11.2020

2021 Half Year Report

Half Year Report for the Half-Year ended September 2020

FY20 Annual Report
29.6.2020

2020 Annual Report

Annual Report for the year ended March 2020

FY20 Half Year Report
28.11.2019

2020 Half Year Report

Half Year Report for the Half-Year ended September 2019

FY19 Annual Report
1.7.2019

2019 Annual Report

Annual Report for the year ended March 2019

FY19 Half Year Report
14.12.2018

2019 Half Year Report

Half Year Report for the Half-Year ended September 2018

FY18 Annual Report
31.7.2018

2018 Annual Report

Annual Report for the year ended March 2018

2018 Half Year Report
14.12.2018

2018 Half Year Report

Report for the Half-Year ended September 2017

FY17 Annual Report
31.7.2017

2017 Annual Report

Annual Report for the year ended March 20217

FY17 Half Year Report
14.12.2016

2017 Half Year Report

Report for the Half-Year ended September 2016

The TruScreen Group manufactures and owns all rights to the TruScreen Cervical Cancer Screening Device.  The system comprises a medical device and process designed to detect the presence in real time of pre-cancerous and cancerous tissue on the cervix.

Company Information

Cervical cancer is the fourth most common cancer in women

In low- and middle-income countries (LMICs) cervical cancer is the second most common form of cancer among women.

5 facts you may not know about cervical cancer